title: Outcomes of statin myopathy after statin withdrawal.
abstract: OBJECTIVE
  To study the outcomes of statin myopathy after statin withdrawal.
  
  
  METHODS
  Sixty-nine patients with mild statin myopathy were studied by chart review.
  
  
  RESULTS
  Mean age at presentation was 62.1 years. Forty-nine (71.0%) of the 69 patients were men. Mean duration of follow-up after statin withdrawal was 18.2 months. Muscle symptoms improved in 9 (13.0%) and completely resolved in 50 (72.5%) patients. Thirteen (18.8%)/69 patients had symptoms lingered beyond 14 months. Creatine kinase (CK) levels were elevated in 52 (75.4%)/69 patients at initial presentation and returned to normal in 11 (21.3%)/52 patients at follow-up. Symptom improvement was not influenced by the initial presence of weakness, CK elevation, or myopathic changes on electromyography or muscle biopsy.
  
  
  CONCLUSIONS
  Muscle symptoms can linger beyond 14 months, and it is difficult to predict which patients will have a prolonged recovery course. CK normalization often lags behind symptom improvement, and this should not be the only indication for muscle biopsy.
authors.affiliation: Department of Neurology, Cleveland Clinic, Cleveland, OH, USA.
authors.forename: Ryan
authors.initials: R
authors.lastname: Armour
authors.forename: Lan
authors.initials: L
authors.lastname: Zhou
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D050171:Dyslipidemias / Q000188:drug therapy; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000473:pathology*; D009135:Muscular Diseases / Q000139:chemically induced* / Q000473:pathology
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors